y90 anti-cd45 monoclonal antibody bc8

mAbexperimentalADC

Chemistry & pharmacology

Multi-specific
No
Payload
90-Yttrium

Oral

No

Parenteral

No

Topical

No

Also known as

  • y90 anti-cd45 monoclonal antibody bc8

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04083183Phase 1/Phase 2 (Phase 2)Sep 30, 2019National Heart, Lung, and Blood Institute (NHLBI), University of Washington
NCT03670966Phase 1/Phase 2 (Phase 2)Nov 12, 2018National Cancer Institute (NCI), University of Washington
NCT01921387Phase 1/Phase 2 (Phase 2)Oct 1, 2013National Cancer Institute (NCI), University of Washington
NCT01678443Phase 1Dec 1, 2012National Cancer Institute (NCI), University of Washington
NCT01503242Phase 1Jan 9, 2012National Cancer Institute (NCI), University of Washington
NCT01300572Phase 1Jan 1, 2012National Cancer Institute (NCI), University of Washington
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of WashingtonAcademic/Hospital6622012
National Cancer Institute (NCI)Government5022012
National Heart, Lung, and Blood Institute (NHLBI)Government1012019
3 organizations
Page 1 / 1